Trials / Completed
CompletedNCT00563355
A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Hospital Authority, Hong Kong · Other Government
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- —
Summary
The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | erythropoietin |
Timeline
- Start date
- 2001-02-01
- Completion
- 2003-11-01
- First posted
- 2007-11-26
- Last updated
- 2011-06-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00563355. Inclusion in this directory is not an endorsement.